BNP Paribas Downgrades Sanofi (SNY) with ‘Unlikely Near-Term Rerating’
Summary
On April 20, BNP Paribas analyst Peter Verdult downgraded Sanofi (NASDAQ:SNY) from ‘Outperform’ to ‘Neutral’, while assigning the stock a price target o...
Description
On April 20, BNP Paribas analyst Peter Verdult downgraded Sanofi (NASDAQ:SNY) from ‘Outperform’ to ‘Neutral’, while assigning the stock a price target o...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source